Table 1.
Results of bivariable analysis of potential risk factors for OIFI occurrence among dogs with immune‐mediated diseases
| Variable | Diagnosed with OIFI, % (n) | Not Diagnosed with OIFI, % (n) | P |
|---|---|---|---|
| Sex | |||
| Female | 6 (4) | 94 (58) | 0.018 |
| Male | 22 (11) | 78 (40) | |
| Age group | |||
| <3 years of age | 19 (3) | 81 (13) | 0.44 |
| ≥3 years of age | 12 (12) | 88 (85) | |
| Azathioprine | |||
| Yes | 11 (4) | 89 (34) | 0.54 |
| No | 15 (11) | 85 (64) | |
| Cyclosporine | |||
| Yes | 20 (13) | 80 (53) | 0.017 |
| No | 4 (2) | 96 (45) | |
| Leflunomide | |||
| Yes | 0 (0) | 100 (3) | 1.0 |
| No | 14 (15) | 86 (95) | |
| Mycophenolate | |||
| Yes | 19 (5) | 81 (21) | 0.33 |
| No | 11 (10) | 89 (77) | |
| Prednisone | |||
| Yes | 13 (15) | 87 (97) | 1.0 |
| No | 0 (0) | 100 (1) | |